Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.ClinicalTrials.gov · 2026-03-02Referee report. For: A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production. [version 2; peer review: 1 approved with reservations, 1 not approved]Faculty of 1000 Research Ltd · 2023-12-31Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 2 approved with reservations]Faculty of 1000 Research Ltd · 2023-12-31Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 1 approved, 3 approved with reservations]Faculty of 1000 Research Ltd · 2023-12-31Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 1 approved with reservations]Faculty of 1000 Research Ltd · 2023-12-31Referee report. For: Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol [version 1; peer review: 3 approved with reservations]Faculty of 1000 Research Ltd · 2023-12-31A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).ClinicalTrials.gov · 2023-11-28Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted ConditionsClinicalTrials.gov · 2023-09-12Referee report. For: Development of a physiologically based pharmacokinetic (PBPK) model of psilocybin and psilocin from magic mushroom in rats and humans [version 1; peer review: 1 not approved]Faculty of 1000 Research Ltd · 2020-12-31Referee report. For: Development of a physiologically based pharmacokinetic (PBPK) model of psilocybin and psilocin from magic mushroom in rats and humans [version 1; peer review: 1 approved with reservations, 1 not approved]Faculty of 1000 Research Ltd · 2020-12-31Referee report. For: A whole genome atlas of 81 Psilocybe genomes as a resource for psilocybin production. [version 1; peer review: 1 not approved]Faculty of 1000 Research Ltd · 2020-12-31